Ovarian cancer: The fallopian tube as the site of origin and opportunities for prevention

Frontiers in Oncology

Volumn 6, Issue MAY, 2016, Pages

  George, Sophia H L ^a,b   Garcia, Ruslan ^a   Slomovitz, Brian M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

BRCA1; BRCA2; Fallopian tubes; Ovarian cancers; Salpingectomy

Indexed keywords

BREAST CANCER; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; FALLOPIAN TUBE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INCIDENCE; LOW RISK POPULATION; MALIGNANT TRANSFORMATION; MORTALITY; NONHUMAN; OVARIECTOMY; OVARY CARCINOMA; REVIEW; SEROSA; UTERINE TUBE LIGATION; UTERINE TUBE STERILIZATION; UTERINE TUBE SURGERY;

EID: 84973530077     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00108     Document Type: Review

References (83)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 65(1):5-29. doi: 10.3322/caac.21254
2. George SH, Shaw P. BRCA and early events in the development of serous ovarian cancer. Front Oncol (2014) 4:5. doi:10.3389/fonc.2014.00005
3. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol (2015) 138(3):741-9. doi:10.1016/j.ygyno.2015.06.017
4. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet (2015) 131(Suppl 2):S111-22. doi:10.1016/j.ijgo.2015.06.007
5. Sogaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand (2006) 85(1):93-105. doi:10.1080/00016340500324621
6. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 72(5):1117-30. doi:10.1086/375033
7. Foulkes WD, Narod SA. Ovarian cancer risk and family history. Lancet (1997) 349(9055):878. doi:10.1016/S0140-6736(05)61782-5
8. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 302(5645):643-6. doi:10.1126/science.1088759
9. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 56(1):265-71
10. Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, et al. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet (2014) 85(1):64-7. doi:10.1111/cge.12132
11. Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Royer R, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat (2011) 125(2):591-6. doi:10.1007/s10549-010-1156-9
12. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 108(44):18032-7. doi:10.1073/pnas.1115052108
13. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol (2016) 2(4):482-90. doi:10.1001/jamaoncol.2015.5495
14. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol (2013) 129(1):258-64. doi:10.1016/j.ygyno.2012.12.016
15. Fathalla MF. Incessant ovulation and ovarian cancer-a hypothesis re-visited. Facts Views Vis Obgyn (2013) 5(4):292-7
16. Moyer VA, Force USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med (2012) 157(12):900-4. doi:10.7326/0003-4819-157-11-201212040-00539
17. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 15(11):668-79. doi:10.1038/nrc4019
18. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol (2008) 9(12):1191-7. doi:10.1016/S1470-2045(08)70308-5
19. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet (1971) 2(7716):163. doi:10.1016/S0140-6736(71)92335-X
20. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One (2009) 4(12):e8534. doi:10.1371/journal.pone.0008534
21. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 24(6):751-65. doi:10.1016/j.ccr.2013.10.013
22. Vang R, Shih IeM, Kurman RJ. Fallopian tube precursors of ovarian low-and high-grade serous neoplasms. Histopathology (2013) 62(1):44-58. doi:10.1111/his.12046
23. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 108(18):7547-52. doi:10.1073/pnas.1017300108
24. George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, et al. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol (2011) 225(1):106-17. doi:10.1002/path.2927
25. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res (2008) 14(13):4067-78. doi:10.1158/1078-0432.CCR-07-4959
26. Tone AA, Virtanen C, Shaw P, Brown TJ. Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis. Clin Cancer Res (2012) 18(16):4334-44. doi:10.1158/1078-0432.CCR-12-0199
27. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature (2012) 490(7418):61-70
28. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474(7353):609-15. doi:10.1038/nature10166
29. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 4(10):2433-7
30. Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 56(16):3622-5
31. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet (1995) 9(4):439-43. doi:10.1038/ng0495-439
32. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 92(7):564-9. doi:10.1093/jnci/92.7.564
33. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol (2006) 101(3):403-10. doi:10.1016/j.ygyno.2005.10.034
34. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 8:17. doi:10.1186/1471-2407-8-17
35. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 4(10):814-9. doi:10.1038/nrc1457
36. Bast RC Jr, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol (2010) 28(22):3545-8. doi:10.1200/JCO.2010.28.5791
37. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 109(2):168-73. doi:10.1016/j.ygyno.2008.01.012
38. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 195(4):451-6. doi:10.1002/path.1000
39. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol (2009) 22(9):1133-8. doi:10.1038/modpathol.2009.89
40. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 211(1):26-35. doi:10.1002/path.2091
41. Piek JM, Dorsman JC, Zweemer RP, Verheijen RH, van Diest PJ, Colgan TJ. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma. Int J Gynecol Pathol (2003) 22(3):315-6. doi:10.1097/01.PGP.0000079451.72325.63 author reply-6
42. Lheureux S, Shaw PA, Karakasis K, Oza AM. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: accuracy of assessment and potential surrogate marker for prevention. Gynecol Oncol (2015) 138(2):235-7. doi:10.1016/j.ygyno.2015.06.014
43. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J Pathol (2010) 222:110-6. doi:10.1002/path.2739
44. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol (2012) 226(3):421-6. doi:10.1002/path.3023
45. Milea A, George SH, Matevski D, et al. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod Pathol (2014) 27(7):991-1001. doi:10.1038/modpathol.2013.218
46. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol (2006) 13(1):1-7. doi:10.1097/01.pap.0000201826.46978.e5
47. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 30(2):230-6. doi:10.1097/01.pas.0000180854.28831.77
48. Finch A, Shaw P, Rosen B, Murphy J, Narod S, Colgan T. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2006) 100(1):58-64. doi:10.1016/j.ygyno.2005.06.065
49. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol (2005) 23(1):127-32. doi:10.1200/JCO.2005.04.109
50. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG (2011) 118(7):814-24. doi:10.1111/j.1471-0528.2011.02920.x
51. Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol (2014) 132(2):280-6. doi:10.1016/j.ygyno.2013.12.009
52. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 25(25):3985-90. doi:10.1200/JCO.2007.12.2622
53. Colgan T, Murphy J, Cole D, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol (2001) 25(10):1283-9. doi:10.1097/00000478-200110000-00009
54. Hirst JE, Gard GB, McIllroy K, Nevell D, Field M. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer (2009) 19(5):826-9. doi:10.1111/IGC.0b013e3181a1b5dc
55. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol (2002) 87(1):52-6. doi:10.1006/gyno.2002.6779
56. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol (2006) 30(10):1222-30. doi:10.1097/01.pas.0000202161.80739.ac
57. Cass I, Walts AE, Barbuto D, Lester J, Karlan B. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. Gynecol Oncol (2014) 134(3):492-7. doi:10.1016/j.ygyno.2014.07.084
58. Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol (2012) 127(1):88-93. doi:10.1016/j.ygyno.2012.06.015
59. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 21(5):846-51. doi:10.1097/IGC.0b013e31821bc7e3
60. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2013) 49(1):132-41. doi:10.1016/j.ejca.2012.07.021
61. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from gynecologic oncology group trial GOG-0199. J Clin Oncol (2014) 32(29):3275-83. doi:10.1200/JCO.2013.54.1987
62. Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer (2013) 23(9):1603-11. doi:10.1097/IGC.0b013e3182a80ac8
63. Jarboe E, Folkins A, Drapkin R, Ince T, Agoston E, Crum C. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2008) 53:127-38. doi:10.1111/j.1365-2559.2007.02938.x
64. Vicus D, Shaw PA, Finch A, Rosen B, Murphy J, Armel S, et al. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol (2010) 118(3):295-8. doi:10.1016/j.ygyno.2010.05.012
65. Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol (2013) 129(2):364-71. doi:10.1016/j.ygyno.2013.01.029
66. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 122(1):139-47. doi:10.1097/AOG.0b013e318291c235
67. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 106(2):djt431. doi:10.1093/jnci/djt431
68. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res (2012) 5(1):13. doi:10.1186/1757-2215-5-13
69. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update (2011) 17(1):55-67. doi:10.1093/humupd/dmq030
70. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (2001) 357(9267):1467-70. doi:10.1016/S0140-6736(00)04642-0
71. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol (2013) 42(2):579-89. doi:10.1093/ije/dyt042
72. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 346(21):1616-22. doi:10.1056/NEJMoa012158
73. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer (2004) 90(8):1492-7. doi:10.1038/sj.bjc.6601692
74. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol (2014) 32(15):1547-53. doi:10.1200/JCO.2013.53.2820
75. Garcia C, Lyon L, Littell RD, Powell CB. Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations. Genet Med (2014) 16(12):896-902. doi:10.1038/gim.2014.48
76. Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila) (2016) 9(1):2-10. doi:10.1158/1940-6207.CAPR-15-0406
77. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol (2014) 210(5):471.e1-11. doi:10.1016/j.ajog.2014.01.003
78. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 304(9):967-75. doi:10.1001/jama.2010.1237
79. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst (2009) 101(2):80-7. doi:10.1093/jnci/djn442
80. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol (2014) 133(2):283-6. doi:10.1016/j.ygyno.2014.02.030
81. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol (2013) 121(4):709-16. doi:10.1097/AOG.0b013e3182864350
82. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 113(5):1027-37. doi:10.1097/AOG.0b013e3181a11c64
83. Narod SA. Salpingectomy to prevent ovarian cancer: a countercurrents series. Curr Oncol (2013) 20(3):145-7. doi:10.3747/co.20.1471